de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S21–3.

Article  PubMed  Google Scholar 

Assogna F, Pellicano C, Savini C, Macchiusi L, Pellicano GR, Alborghetti M, et al. Drug choices and advancements for managing depression in Parkinson’s disease. Curr Neuropharmacol. 2020;18:277–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 2018;17:559–68.

Article  PubMed  Google Scholar 

Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease–epidemiology, mechanisms and management. Nat Rev Neurol. 2011;8:35–47.

Article  PubMed  Google Scholar 

Bhome R, Zarkali A, Thomas GEC, Iglesias JE, Cole JH, Weil RS. Thalamic white matter macrostructure and subnuclei volumes in Parkinson’s disease depression. NPJ Parkinsons Dis. 2022;8:2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenka A, Ingalhalikar M, Shah A, Saini J, Arumugham SS, Hegde S, et al. Hippocampal subfield atrophy in patients with Parkinson’s disease and psychosis. J Neural Transm (Vienna). 2018;125:1361–72.

Article  CAS  PubMed  Google Scholar 

Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson’s disease. Psychosomatics. 2010;51:474–9.

CAS  PubMed  PubMed Central  Google Scholar 

Wang XM, Zhang YG, Li AL, Long ZH, Wang D, Li XX, et al. Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2016;20:3853–6.

PubMed  Google Scholar 

Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roddy DW, Farrell C, Doolin K, Roman E, Tozzi L, Frodl T, et al. The Hippocampus in depression: more than the sum of its parts? advanced hippocampal substructure segmentation in depression. Biol Psychiatry. 2019;85:487–97.

Article  PubMed  Google Scholar 

Calabresi P, Castrioto A, Di Filippo M, Picconi B. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson’s disease. Lancet Neurol. 2013;12:811–21.

Article  CAS  PubMed  Google Scholar 

Huang Y, Coupland NJ, Lebel RM, Carter R, Seres P, Wilman AH, et al. Structural changes in hippocampal subfields in major depressive disorder: a high-field magnetic resonance imaging study. Biol Psychiatry. 2013;74:62–8.

Article  PubMed  Google Scholar 

Györfi O, Nagy H, Bokor M, Moustafa AA, Rosenzweig I, Kelemen O, et al. Reduced CA2-CA3 Hippocampal subfield volume is related to depression and normalized by l-DOPA in newly diagnosed Parkinson’s disease. Front Neurol. 2017;8:84.

Article  PubMed  PubMed Central  Google Scholar 

Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov Disord. 2012;27:84–89.

Article  CAS  PubMed  Google Scholar 

Mosser CA, Baptista S, Arnoux I, Audinat E. Microglia in CNS development: Shaping the brain for the future. Prog Neurobiol. 2017;149-150:1–20.

Article  PubMed  Google Scholar 

Woodburn SC, Bollinger JL, Wohleb ES. The semantics of microglia activation: neuroinflammation, homeostasis, and stress. J Neuroinflammation. 2021;18:258.

Article  PubMed  PubMed Central  Google Scholar 

Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl. 2006;70:373–81.

Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer’s disease. Neuron. 2018;100:1337–1353.e5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–89.

Article  CAS  PubMed  Google Scholar 

Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164–78.

Article  CAS  PubMed  Google Scholar 

Cong Q, Soteros BM, Wollet M, Kim JH, Sia GM. The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development. Nat Neurosci. 2020;23:1067–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation. 2020;17:354.

Article  PubMed  PubMed Central  Google Scholar 

Crider A, Feng T, Pandya CD, Davis T, Nair A, Ahmed AO, et al. Complement component 3a receptor deficiency attenuates chronic stress-induced monocyte infiltration and depressive-like behavior. Brain Behav Immun. 2018;70:246–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang R, Wang QB, Xie T, Guo KH. The role of glial cell activation mediated by complement system C1q/C3 in depression-like behavior in mice. J SUN Yat-sen Univ (Med Sci). 2021;42:328–37.

Google Scholar 

Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientis. 2015;21:44–61.

Article  Google Scholar 

Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:837–44.

Article  CAS  PubMed  Google Scholar 

Zhang Q, Wu W, Fan Y, Li Y, Liu J, Xu Y, et al. The safety and efficacy of botulinum toxin A on the treatment of depression. Brain Behav. 2021;11:e2333.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luvisetto S. Botulinum neurotoxins in central nervous system: an overview from animal models to human therapy. Toxins (Basel). 2021;13:751.

Article  CAS  PubMed  Google Scholar 

Li Y, Liu J, Liu X, Su CJ, Zhang QL, Wang ZH, et al. Antidepressant-like action of single facial injection of botulinum neurotoxin A is associated with augmented 5-HT levels and BDNF/ERK/CREB pathways in mouse brain. Neurosci Bull. 2019;35:661–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu C, Wang K, Yu T, Liu H. Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson’s disease and depression. Am J Transl Res. 2021;13:2717–23.

CAS  PubMed  PubMed Central  Google Scholar 

Lyu A, Fan Y, Tang L, Guo X, Liu J, Huang Y, et al. Clinical study on the efficacy and safety of botulinum toxin A in the treatment of Parkinson′s disease with depression. Chin J Neurol. 2019;52:745–51.

Google Scholar 

Ham HJ, Yeo IJ, Jeon SH, Lim JH, Yoo SS, Son DJ, et al. Botulinum toxin A ameliorates neuroinflammation in the MPTP and 6-OHDA-induced Parkinson’s disease models. Biomol Ther (Seoul). 2022;30:90–97.

Article  CAS  PubMed  Google Scholar 

Antipova V, Holzmann C, Hawlitschka A, Witt M, Wree A. Antidepressant-like properties of intrastriatal botulinum neurotoxin-A injection in a unilateral 6-OHDA rat model of Parkinson’s disease. Toxins (Basel). 2021;13:505.

Article  CAS  PubMed  Google Scholar 

Cong Q, Soteros BM, Huo A, Li Y, Tenner AJ, Sia GM. C1q and SRPX2 regulate microglia mediated synapse elimination during early development in the visual thalamus but not the visual cortex. Glia. 2022;70:451–65.

Article  CAS  PubMed  Google Scholar 

Young K, Morrison H. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using ImageJ. J Vis Exp. 2018;136:57648.

Sanchez K, Darling JS, Kakkar R, Wu SL, Zentay A, Lowry CA, et al. Mycobacterium vaccae immunization in rats ameliorates features of age-associated microglia activation in the amygdala and hippocampus. Sci Rep. 2022;12:2165.

Article  CAS  PubMed  PubMed Central